In short
This article discusses the ongoing clinical trials investigating TARA-002, a novel treatment for high-grade non-muscle invasive bladder cancer. TARA-002 is an inactivated form of Streptococcus Pyogenes, Group A, Type 3, Strain Su, which is being studied for its potential anti-tumor activity when administered intravesically (directly into the bladder). The trials aim to evaluate the safety, efficacy, and quality of life impacts of this innovative therapy for patients with this challenging form of bladder cancer.
At a glance
- Study Type
- Phase 1b/2, dose expansion, open-label study
- Treatment
- TARA-002 (inactivated Streptococcus Pyogenes) administered intravesically
- Target Condition
- High-grade non-muscle invasive bladder cancer (CIS ± Ta/T1)
- Study Cohorts
- Cohort A: BCG-naïve or >24 months since BCG; Cohort B: BCG-unresponsive CIS
- Primary Endpoints
- Incidence of high-grade complete response at any time
- Secondary Endpoints
- Safety profile, cytokine level changes, quality of life, duration of response, progression-free survival, overall survival
- Follow-up Duration
- Up to 24 months
- Key Eligibility Criteria
- Adults 18+, confirmed high-grade NMIBC, adequate organ function, no significant urinary incontinence
- Key Exclusion Criteria
- Penicillin allergy, predominant non-urothelial histology, nodal or metastatic disease, history of ≥T2 bladder cancer
What is TARA-002?
TARA-002 is an investigational medication being studied for the treatment of high-grade non-muscle invasive bladder cancer. It is a biological product derived from inactivated Group A Streptococcus pyogenes, specifically type 3, strain SU. This medication is administered directly into the bladder, a method known as intravesical instillation.
Medical Condition: Non-Muscle Invasive Bladder Cancer
Non-muscle invasive bladder cancer (NMIBC) is a type of bladder cancer that has not spread into the muscle layer of the bladder wall. High-grade NMIBC is a more aggressive form of this cancer. The clinical trial focuses on patients with high-grade non-muscle invasive carcinoma in situ (CIS), which is a flat, high-grade cancer confined to the inner layer of the bladder.
How TARA-002 Works
While the exact mechanism of action is not fully described in the trial information, TARA-002 is likely designed to stimulate the immune system to fight cancer cells in the bladder. As a biological product derived from inactivated bacteria, it may work similarly to other immunotherapies used in bladder cancer treatment.
Clinical Trial Overview
The clinical trial for TARA-002 is a Phase 1b/2 study, which means it is in the early stages of testing in humans. The main objectives of the trial are:
- To assess the safety of TARA-002 when administered into the bladder
- To evaluate the anti-tumor activity (effectiveness) of TARA-002
- To study changes in cytokine levels (proteins involved in immune responses) after treatment
- To assess the quality of life of patients receiving the treatment
Eligibility Criteria
To participate in the trial, patients must meet certain criteria, including:
- Being 18 years or older
- Having a confirmed diagnosis of high-grade non-muscle invasive CIS
- For some parts of the study, having cancer that has not responded to or has returned after previous treatment with BCG (a standard immunotherapy for bladder cancer)
- Not having certain medical conditions or a history of other cancers
Treatment Process
TARA-002 is administered directly into the bladder through a process called intravesical instillation. Patients are typically asked to hold the medication in their bladder for about 2 hours to allow it to work effectively.
Potential Benefits
The potential benefits being studied include:
- Reduction or elimination of cancer cells in the bladder (complete response)
- Longer periods without cancer recurrence
- Improved survival rates
- Delay or avoidance of more invasive treatments like bladder removal (cystectomy)
Safety Considerations
As with any experimental treatment, there may be risks and side effects. The trial is designed to carefully monitor for any adverse events. Patients with a penicillin allergy are excluded from the study due to the bacterial origin of TARA-002.
Quality of Life Assessment
An important aspect of this trial is the assessment of patients' quality of life. This is done using standardized questionnaires (EORTC QLQ-C30 and QLQ-NMIBC24) that help researchers understand how the treatment affects patients' daily lives and overall well-being.